---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-23-000074"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:31:14.881623+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q4 core revenue $26-27M, seq growth 4-9%; restructuring on track

## Summary
- Preliminary Q4 core revenue $26-27M (4-9% sequential growth); FY 2022 ~$94-95M.
- Restructuring reduces opex >$30M (20%+); headcount cut 15%, real estate 25%.
- Targets positive free cash flow by Q4 2024; year-end cash $165M.
- Non-GAAP gross margin goal 65-68% by end of 2023; GAAP 52-55%.
- Appointed Betsy Jensen CHRO; Hyperion XTi imaging system on track with 2 early units shipped.

## SEC filing metadata
- accession: 0000950142-23-000074
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/0000950142-23-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/eh230318897_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-23-000074
- JSON: https://secwatch.observer/filing/0000950142-23-000074.json
- Plain text: https://secwatch.observer/filing/0000950142-23-000074.txt

## Key facts
- Earnings Releases
  STANDARD BIOTOOLS INC. reported the fiscal year ended December 31, 2022 results: revenue in the range of approximately $94 million–$95 million. Guidance reaffirmed.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: in the range of approximately $94 million–$95 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: For the full year, core product and service revenues are expected to be in the range of approximately $94 million–$95 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/0000950142-23-000074-index.htm
- Earnings Releases
  STANDARD BIOTOOLS INC. reported the fourth quarter ended December 31, 2022 results: revenue in the range of $26 million–$27 million. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: in the range of $26 million–$27 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: For the fourth quarter, core product and service revenues (Genomics and Proteomics excluding discontinued and COVID-19 related products) are expected to be in the range of $26 million–$27 million, representing approximately 4%–9% sequential quarterly growth.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/0000950142-23-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.